A Phase 2 interventional study of REGN475 and REGN475 in Sciatica, sponsored by Regeneron Pharmaceuticals. Completed at 30 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-12-08.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
This is a phase 2, randomized, double-blind, parallel-group, single dose study to evaluate the safety and efficacy of 2 dose levels of REGN475 compared with placebo in patients with sciatic pain. Enrollment of approximately 50 patients in each of the 3 treatment arms is expected at up to 35 US sites, for a total enrollment of approximately 150 patients. Patients will receive 1 injection under the skin of either active or placebo REGN475, and be followed over 10 visits for 12 weeks.
139 studies on the registry are indexed under Sciatica; 29 are open to participants now.
This study's enrollment of 159 is above the median of 66 across 111 interventional studies indexed under Sciatica.
Browse Sciatica studies →Regeneron Pharmaceuticals is the lead sponsor of 400 studies on the registry; 91 are open to participants now.
Of its 120 completed or terminated interventional studies of FDA-regulated products, 77 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Placebo Injection
subcutaneous injection of REGN475
Drug: REGN475
subcutaneous injection of REGN475
Drug: REGN475
Single Subcutaneous injection dose level 1
Single subcutaneous injection dose level 2
Placebo Subcutaneous injection
Sciatic pain between baseline and end of week 4
Time frame: 4 weeks
Additional measures of sciatic pain.
Time frame: 6 weeks
This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Regeneron Pharmaceuticals